{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T09:38:35Z","timestamp":1775554715721,"version":"3.50.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.bulcan.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T11:30:51Z","timestamp":1719315051000},"page":"S135-S145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"S","title":["Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques pour les LAM p\u00e9diatriques (SFGM-TC)"],"prefix":"10.1016","volume":"112","author":[{"given":"C\u00e9cile","family":"Renard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alizee","family":"Corbel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Paillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9cile","family":"Pochon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Simon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nimrod","family":"Buchbinder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mony","family":"Fahd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bulcan.2024.02.006_bib0280","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/bmt.2016.293","article-title":"Cytogenetics and outcome of allogeneic transplantation in first remission of acute myeloid leukemia: the French pediatric experience","volume":"52","author":"Alloin","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.bulcan.2024.02.006_bib0285","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2021005164","article-title":"Gilteritinib combination therapies in pediatric patients with FLT3-mutated acute myeloid leukemia","volume":"5","author":"McCall","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.006_bib0290","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol Off"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.006_bib0295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11912-020-01009-3","article-title":"Acute Myeloid Leukemia in children: emerging paradigms in genetics and new approaches to therapy","volume":"23","author":"Conneely","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0300","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1097\/HS9.0000000000000031","article-title":"Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the french ELAM02\u00a0Study Group","volume":"2","author":"Marceau-Renaut","year":"2018","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0305","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.12074","article-title":"Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation","volume":"160","author":"Lee","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.006_bib0310","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1080\/08880018.2020.1717697","article-title":"Assessment of chimerism and immunomodulation to prevent post-transplantation relapse in childhood acute myeloblastic leukemia: is it the right approach?","volume":"37","author":"Cousin","year":"2020","journal-title":"Pediatr Hematol Oncol"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.006_bib0315","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/bmt.2016.360","article-title":"Outcome after failure of allogeneic hematopoietic stem cell transplantation in children with acute leukemia: a study by the soci\u00e9t\u00e9 Francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"52","author":"Roux","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"12S","key":"10.1016\/j.bulcan.2024.02.006_bib0320","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.bulcan.2017.05.009","article-title":"[Preventative and therapeutic relapse strategies after allogeneic hematopoietic stem cell transplantation: Guidelines from the Francophone society of bone marrow transplantation and cellular therapy (SFGM-TC)]","volume":"104","author":"Yafour","year":"2017","journal-title":"Bull Cancer (Paris)"},{"issue":"6","key":"10.1016\/j.bulcan.2024.02.006_bib0325","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"Bazarbachi","year":"2020","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.006_bib0330","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/08880018.2020.1829220","article-title":"Azacitidine and prophylactic donor lymphocyte infusions after hematopoietic stem cell transplantation for pediatric high-risk acute myeloid leukemia","volume":"38","author":"Huschart","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"10.1016\/j.bulcan.2024.02.006_bib0335","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1182\/blood-2019-129557","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ AML Improves event-free survival and reduces relapse risk: a report from the children's oncology group protocol AAML1031","volume":"134","author":"Pollard","year":"2019","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.006_bib0340","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/bjh.15593","article-title":"A phase 1\/2, open-label, dose-escalation study of midostaurin in children with relapsed or refractory acute leukaemia","volume":"185","author":"Zwaan","year":"2019","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0345","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2013.08.012","volume":"20","author":"de Lima","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11S","key":"10.1016\/j.bulcan.2024.02.006_bib0350","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"[How we harmonize HSCT clinical practices among the SFGM-TC centers]","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"11","key":"10.1016\/j.bulcan.2024.02.006_bib0355","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1038\/bmt.2016.167","article-title":"Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT","volume":"51","author":"Tsirigotis","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.006_bib0360","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41375-019-0584-8","article-title":"Hematopoietic stem cell transplantation for children with acute myeloid leukemia-results of the AML SCT-BFM 2007\u00a0trial","volume":"34","author":"Sauer","year":"2020","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.006_bib0365","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1038\/s41409-019-0438-z","article-title":"Prognosis of relapse after hematopoietic cell transplant (HCT) for treatment of leukemia or myelodysplastic syndrome (MDS) in children","volume":"54","author":"Dahlberg","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.bulcan.2024.02.006_bib0370","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3390\/genes12060924","article-title":"Cytogenetics of pediatric acute myeloid leukemia: a review of the current knowledge","volume":"12","author":"Quessada","year":"2021","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.bulcan.2024.02.006_bib0375","doi-asserted-by":"crossref","first-page":"e28979","DOI":"10.1002\/pbc.28979","article-title":"Treatment of acute myeloid leukemia in children: a practical perspective","volume":"68","author":"Egan","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"19","key":"10.1016\/j.bulcan.2024.02.006_bib0380","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.3390\/cancers13194817","article-title":"Impact of KMT2A Rearrangement and CSPG4\u00a0Expression in Pediatric Acute Myeloid Leukemia","volume":"13","author":"Hoffmeister","year":"2021","journal-title":"Cancers"},{"issue":"16","key":"10.1016\/j.bulcan.2024.02.006_bib0385","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","article-title":"Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel","volume":"120","author":"Creutzig","year":"2012","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2024.02.006_bib0390","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/bmt.2015.234","article-title":"Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation","volume":"51","author":"Jedlickova","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.006_bib0395","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/bmt.2016.326","article-title":"Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation for high-risk AML","volume":"52","author":"Legrand","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.006_bib0400","doi-asserted-by":"crossref","first-page":"839e1","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"10.1016\/j.bulcan.2024.02.006_bib0405","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","article-title":"Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Guillaume","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2024.02.006_bib0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.patbio.2014.05.011","article-title":"Prophylactic, preemptive and curative use of donor lymphocyte infusion in patients undergoing allogeneic stem cell transplantation: guidelines of the SFGM-TC","volume":"62","author":"Guillaume","year":"2014","journal-title":"Pathol Biol (Paris)"},{"issue":"1S","key":"10.1016\/j.bulcan.2024.02.006_bib0415","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.bulcan.2018.10.002","article-title":"Donor Lymphocyte Infusions (DLI): guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"106","author":"De Vos","year":"2019","journal-title":"Bull Cancer (Paris)"},{"issue":"21","key":"10.1016\/j.bulcan.2024.02.006_bib0420","doi-asserted-by":"crossref","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","article-title":"A phase 3\u00a0randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients","volume":"4","author":"Oran","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2024.02.006_bib0425","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00277-022-04821-y","article-title":"Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation","volume":"101","author":"Wattebled","year":"2022","journal-title":"Ann Hematol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.006_bib0430","doi-asserted-by":"crossref","first-page":"e27284","DOI":"10.1002\/pbc.27284","article-title":"Low-dose azacitidine maintenance therapy after allogeneic stem cell transplantation for high-risk pediatric acute myeloid leukemia","volume":"65","author":"Tamura","year":"2018","journal-title":"Pediatr Blood Can"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0435","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/nm.4439","article-title":"The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions","volume":"24","author":"Bolouri","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.006_bib0440","doi-asserted-by":"crossref","first-page":"664","DOI":"10.3324\/haematol.2019.240747","article-title":"Maintenance therapy for FLT3-ITD-mutated acute myeloid leukemia","volume":"106","author":"Burchert","year":"2021","journal-title":"Haematologica"},{"issue":"26","key":"10.1016\/j.bulcan.2024.02.006_bib0445","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J Clin Oncol Off"},{"issue":"18","key":"10.1016\/j.bulcan.2024.02.006_bib0450","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3 -mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0455","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00277-021-04674-x","article-title":"Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation","volume":"101","author":"Zhao","year":"2022","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.bulcan.2024.02.006_bib0460","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1111\/cas.15048","article-title":"Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"112","author":"Wei","year":"2021","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.bulcan.2024.02.006_bib0465","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.006_bib0470","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.3390\/cancers14082025","article-title":"Azacitidine plus venetoclax for the treatment of relapsed and newly diagnosed acute myeloid leukemia patients","volume":"14","author":"Garciaz","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.bulcan.2024.02.006_bib0475","doi-asserted-by":"crossref","first-page":"810387","DOI":"10.3389\/fonc.2021.810387","article-title":"Hypomethylating agent-based combination therapies to treat post-hematopoietic stem cell transplant relapse of acute myeloid leukemia","volume":"11","author":"Ciotti","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.006_bib0480","doi-asserted-by":"crossref","first-page":"e28398","DOI":"10.1002\/pbc.28398","article-title":"Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia","volume":"67","author":"Winters","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2024.02.006_bib0485","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bjh.15725","article-title":"CBFA2T3-GLIS2-positive acute myeloid leukaemia. A peculiar paediatric entity","volume":"184","author":"Masetti","year":"2019","journal-title":"Br J Haematol"},{"issue":"15","key":"10.1016\/j.bulcan.2024.02.006_bib0490","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2018-05-849059","article-title":"Prognostic impact of t(16;21)(p11;q22) and t(16;21)(q24;q22) in pediatric AML: a retrospective study by the I-BFM Study Group","volume":"132","author":"Noort","year":"2018","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.bulcan.2024.02.006_bib0495","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10\u00a0and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol Off"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.006_bib0500","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s40262-020-00888-w","article-title":"Pharmacokinetic profile of gilteritinib: a novel FLT-3\u00a0tyrosine kinase inhibitor","volume":"59","author":"James","year":"2020","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.bulcan.2024.02.006_bib0505","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/FPC.0000000000000279","article-title":"PharmGKB summary: sorafenib pathways","volume":"27","author":"Gong","year":"2017","journal-title":"Pharmacogenet Genomics"},{"issue":"18","key":"10.1016\/j.bulcan.2024.02.006_bib0510","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1200\/JCO.21.01612","article-title":"Sorafenib in combination with standard chemotherapy for children with high allelic ratio FLT3\/ITD+ acute myeloid leukemia: a report from the children's oncology group protocol AAML1031","volume":"40","author":"Pollard","year":"2022","journal-title":"J Clin Oncol Off"},{"issue":"21","key":"10.1016\/j.bulcan.2024.02.006_bib0515","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/1078-0432.CCR-11-3284","article-title":"A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a children's oncology group phase I consortium report","volume":"18","author":"Widemann","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"24","key":"10.1016\/j.bulcan.2024.02.006_bib0520","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/1078-0432.CCR-19-0470","article-title":"Sorafenib population pharmacokinetics and skin toxicities in children and adolescents with refractory\/relapsed leukemia or solid tumor malignancies","volume":"25","author":"Inaba","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.bulcan.2024.02.006_bib0525","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/00498254.2015.1109160","article-title":"The drug\u2013drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4","volume":"46","author":"Wang","year":"2016","journal-title":"Xenobiotica"},{"issue":"10","key":"10.1016\/j.bulcan.2024.02.006_bib0530","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1002\/pbc.24619","article-title":"Alternative formulations of sorafenib for use in children: Sorafenib Formulations for Use in Children","volume":"60","author":"Navid","year":"2013","journal-title":"Pediatr Blood Can"},{"key":"10.1016\/j.bulcan.2024.02.006_bib0535","first-page":"jcph.2140","article-title":"Impact of multiple concomitant CYP3A inhibitors on venetoclax pharmacokinetics: a PBPK and population pk-informed analysis","author":"Mukherjee","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.bulcan.2024.02.006_bib0540","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s40261-022-01172-4","article-title":"Bioavailability evaluation of venetoclax lower-strength tablets and oral powder formulations to establish interchangeability with the 100mg tablet","volume":"42","author":"Badawi","year":"2022","journal-title":"Clin Drug Investig"},{"issue":"1","key":"10.1016\/j.bulcan.2024.02.006_bib0545","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/j.bulcan.2018.07.020","article-title":"Pharmacie clinique en unit\u00e9 de greffe de moelle osseuse et th\u00e9rapie cellulaire\u2013quelles activit\u00e9s mettre en place? Recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC)","volume":"106","author":"Forcade","year":"2019","journal-title":"Bull Cancer (Paris)"},{"issue":"12","key":"10.1016\/j.bulcan.2024.02.006_bib0275","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of therapeutic drug monitoring of anticancer drugs part two\u2013Targeted therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur J Cancer"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124001097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455124001097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T18:51:07Z","timestamp":1736275867000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455124001097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0007455124001097"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.006","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques pour les LAM p\u00e9diatriques (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}